Successful treatment of transplant-associated microangiopathy with rituximab.
The microangiopathic anaemia with thrombocytopenia--which can occur after haematopoietic stem cell transplant--resembles thrombotic thrombocytopenic purpura but has different pathophysiology and does not respond to plasma exchange. We describe a patient with severe manifestations of this disorder who recovered promptly following treatment with rituximab, an anti-CD20 antibody.
Marr
Helen
H
McDonald
Emma-Jane
EJ
Merriman
Eileen
E
Smith
Mark
M
Mangos
Hilda
H
Stoddart
Catherine
C
Ganly
Peter
P
D000328:Adult; D000741:Anemia, Aplastic / Q000175:diagnosis / Q000601:surgery; D000743:Anemia, Hemolytic / Q000188:drug therapy* / Q000209:etiology*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D016026:Bone Marrow Transplantation / Q000009:adverse effects* / Q000379:methods; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D011697:Purpura, Thrombotic Thrombocytopenic / Q000188:drug therapy / Q000209:etiology; D018570:Risk Assessment; D000069283:Rituximab; D012720:Severity of Illness Index; D014184:Transplantation, Homologous; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab